HIV Disclosure and Medication Adherence, a Pilot Study (RSAD-VIH-11)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators believe that disclosure of HIV status could influence medication adherence. If disclosure leads to social support, adherence could be improved. This study purpose is to assess correlation between disclosure and medication adherence, and to describe people whose HIV status has been disclosed to.
| Condition |
|---|
|
HIV Infection |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
| Official Title: | HIV Disclosure and Medication Adherence, a Pilot Study |
- Patient Adherence [ Time Frame: 30 days before survey ] [ Designated as safety issue: No ]Electronic monitoring of adherence during 30 days before survey
- Patient Adherence [ Time Frame: 90 days before survey ] [ Designated as safety issue: No ]Electronic monitoring of adherence during 90 days before survey
| Estimated Enrollment: | 120 |
| Study Start Date: | April 2012 |
| Estimated Study Completion Date: | March 2013 |
| Estimated Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
Pharmacists administer a questionnaire to each consecutive subject taking part in the adherence-enhancing program at the pharmacy of the Department of Ambulatory Care And Community Medicine in Lausanne. This questionnaire assesses disclosure, response to disclosure, and living situation.
Adherence is measured by electronic monitoring and pill count.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients enrolled in the adherence-enhancing program at ther pharmacy of Department of Ambulatory Care and Community Medicine in Lausanne
Inclusion Criteria:
- HIV Infection
- Enrolled in the adherence-enhancing program
Exclusion Criteria:
- Inclusion visit
- Not french or english speaker
Contacts and Locations| Switzerland | |
| Policlinique Médicale Universitaire | |
| Lausanne, Vaud, Switzerland, 1011 | |
| Principal Investigator: | Marie-Paule Schneider, PhD | Policlinique Médicale Universitaire |
| Principal Investigator: | Aurélie Gertsch, PhD-Student | Policlinique Médicale Universitaire |
| Study Chair: | Olivier Bugnon, Professor | Policlinique Médicale Universitaire |
| Study Chair: | Matthias Cavassini, MD | Centre Hospitalier Universitaire Vaudois |
More Information
No publications provided
| Responsible Party: | Marie Schneider, Pharmacist, PhD, Policlinique Médicale Universitaire |
| ClinicalTrials.gov Identifier: | NCT01621412 History of Changes |
| Other Study ID Numbers: | RSAD-VIH-2011 |
| Study First Received: | May 31, 2012 |
| Last Updated: | June 13, 2012 |
| Health Authority: | Switzerland: Ethikkommission |
Keywords provided by Policlinique Médicale Universitaire:
|
Medication Adherence HIV infection Disclosure |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on May 21, 2013